Technology & Platform
Leveraging our novel technologies to support development pipelines
While ForDoz Pharma is adept at the production of conventional injectables, we also have the expertise to produce complex injectable therapeutics, advancing and commercializing novel drug products through three core technology platforms:
Liposomal &
nanoparticle-based delivery for targeted, controlled release
Microsphere & polymer–based systems to tailor sustained-release profiles
in situ depot
formulations enabling long-acting injectable therapies
Our development and commercialization begin with crafting high-quality generics of established injectables, then progressing to innovative 505(b)(2) candidates that deliver enhanced clinical outcomes.
FDA-Approved Product
As our first liposome pharmaceutical product to enter the US market, the 2024 FDA approval of our ANDA for doxorubicin HCl liposome injection marked a significant milestone for ForDoz. We are commercially manufacturing this approved liposomal product in our cGMP-compliant commercial manufacturing facility located in East Windsor, New Jersey.
The product is being marketed in the U.S. through our marketing and sales partner, Lupin Pharmaceuticals, Inc.
Please read the complete prescribing information.
|
PRODUCT
|
SIZE
|
||
|---|---|---|---|
| DOXOrubicin Hydrochloride Liposome Injection | 20 mg/10mL | (2mg/mL) | (NDC 70748-339-01) |
| 50 mg/25mL | (2mg/mL) | (NDC 70748-340-01 |
- PRODUCT
- DOXOrubicin Hydrochloride Liposome Injection
- SIZE
- 20 mg/10mL (2mg/mL)
- (NDC 70748-339-01)
- 50 mg/25mL (2mg/mL)
- (NDC 70748-340-01
Our Sterile Injectables Pipeline
Working to Advance Your Conventional and Complex Injectables Program
Let us put our expertise and capacity to work to support the end-to-end needs of your conventional and complex injectable program, from early development and regulatory approval to commercial manufacturing.